Bio-Techne Corp (TECH) Stock Price & Analysis
Bio-Techne Corp (TECH) fell 0.24% to USD 71.6 as of July 25, 2026 at 02:24 UTC, according to Nexqual real-time market data.
TECH last closed at USD 71.77; the session ranged USD 71.58–71.94 on volume of 2,055,638 shares. Market capitalization is $11.16B, with a 52-week range of USD 43.2–72.16 (NMS). Source: Nexqual, July 25, 2026 at 02:24 UTC.
Key Statistics (as of July 25, 2026 at 02:24 UTC)
| Price | USD 71.6 |
|---|---|
| Change | ▼ 0.24% (down) |
| Previous Close | USD 71.77 |
| Open | USD 71.89 |
| Day Range | USD 71.58 – 71.94 |
| 52-Week Range | USD 43.2 – 72.16 |
| Volume | 2,055,638 shares |
| Market Cap | $11.16B |
| Exchange | NMS |
Technical Analysis (TECH)
Nexqual's technical model rates TECH "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 02:24 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 76.35 (overbought) |
| vs SMA50 | Above (USD 59.6) |
| MACD | 3.2 (positive) |
Analyst Ratings (TECH)
Wall Street analysts rate TECH "Hold" based on 12 analysts, with a mean price target of USD 70 (range USD 50–73), per Nexqual as of July 25, 2026 at 02:24 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 70 |
| High Target | USD 73 |
| Low Target | USD 50 |
| Buy / Hold / Sell | 2 / 13 / 0 |
Earnings (TECH)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.52 |
| Revenue Estimate | $314.76M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.53 vs est 0.53 ▼ miss |
| 2025-12-31 | USD 0.46 vs est 0.43 ▲ beat |
| 2025-09-30 | USD 0.42 vs est 0.42 ▼ miss |
| 2025-06-30 | USD 0.53 vs est 0.5 ▲ beat |
Source: Nexqual, July 25, 2026 at 02:24 UTC.
Financials & Fundamentals (TECH)
| Total Revenue | $1.21B |
|---|---|
| Revenue Growth (YoY) | -1.50% |
| Gross Margin | +66.40% |
| Operating Margin | +25.19% |
| Profit Margin | +9.05% |
| ROE | +5.34% |
| Debt / Equity | 13.92 |
| Current Ratio | 4.49 |
| Total Cash | $214.11M |
| Total Debt | $290.32M |
| Free Cash Flow | $299.85M |
Source: Nexqual, July 25, 2026 at 02:24 UTC.
Financial Health Score (TECH)
Nexqual rates Bio-Techne Corp's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 02:24 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 66%, operating 25% |
| Balance Sheet | Strong — $214M cash vs $290M debt |
| Cash Flow | Strong — FCF $300M, 25% margin |
| Efficiency | Mixed — ROE 5%, ROA 7.5% |
Ownership (TECH)
| Insider Ownership | +0.31% |
|---|---|
| Institutional Ownership | +117.92% |
| Shares Outstanding | 155.81M |
| Float | 155.96M |
| Short % of Float | +11.66% |
Source: Nexqual, July 25, 2026 at 02:24 UTC.
Leadership (TECH)
Bio-Techne Corp is led by Kim Kelderman (age 57), CEO, President & Director, per Nexqual as of July 25, 2026 at 02:24 UTC.
| CEO, President & Director | Kim Kelderman (age 57) |
|---|---|
| Executive VP of Finance & CFO | James T. Hippel (age 54) |
| President of Protein Sciences Segment | William A. Geist (age 56) |
| VP & CTO | Gary J. Latham |
| Vice President of Investor Relations | David Clair C.F.A. |
Major Backers & Investors (TECH)
Notable institutional backers of Bio-Techne Corp include Morgan Stanley, Invesco, FMR, LLC, according to Nexqual as of July 25, 2026 at 02:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 5.45% |
| Invesco | 5.14% |
| FMR, LLC | 5.05% |
| Wellington Management | 3.27% |
| Maverick Capital Ltd. | 3.03% |
| Eaton Vance Growth Trust-Eaton Vance Atlanta Capital SMID-Cap Fund | 2.54% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.47% |
| BlackRock | 9.15% |
| State Street | 3.75% |
| Geode Capital | 3.27% |
Source: Nexqual, July 25, 2026 at 02:24 UTC.
From Bio-Techne Corp's Latest SEC 10-K Filing (filed 2025-08-22)
Key Strengths & Strategy (as disclosed to the SEC)
- Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
- The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology.
- The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
- This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CRL | Charles River Laboratories Inte | USD 226.58 | ▲ 3.6% |
| BIO | Bio-Rad Laboratories, Inc. | USD 314.46 | ▲ 2.78% |
| TFX | Teleflex Incorporated | USD 132.1 | ▼ 2% |
| STE | STERIS plc (Ireland) | USD 214.07 | ▲ 1.66% |
| MTD | Mettler-Toledo International, I | USD 1,327.18 | ▲ 3.21% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:24 UTC. This page is informational and not investment advice.